Sandoz Canada Aims For 10 Biosimilar Launches In Next Decade
Pegfilgrastim And Rituximab Biosimilars Coming Soon
Speaking with Generics Bulletin as Sandoz Canada unveiled its landmark public education campaign, The Biosimilars Generation, Karine Matteau, the company’s biosimilars leader, talked about how it plans to remain a leader in the biosimilars field as well as the company’s response to the COVID-19 pandemic.
You may also be interested in...
Sandoz Canada has taken another “important step as we pursue our ambition to become the leading biosimilars and generics company” with the launch of biosimilar enoxaparin.
Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.
Sandoz Canada is looking to roll out its biosimilar to AbbVie’s Humira early in the new year following approval from Health Canada, with multiple other adalimumab candidates also reportedly approved.